Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ono Pharmaceutical Co., Ltd. (4528.T)
Osaka, JP
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.03% | +8.27% | +2.49% | +0.69% | +27.45% | +16.70% | +65.09% | -0.78% | +3.67% | -50.70% | +225.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 8 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+5.9% Q1'26: +5.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+39.5% ★ Q1'26: +112.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+25.3% Q1'26: +41.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+20.0% ★ Q1'26: +10.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+10.5% ★ Q1'26: +4.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.86× ★ Q1'26: 1.37× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 11 Rev. Ana. 10 EPS Ana. |
Mar 2027 10 Rev. Ana. 9 EPS Ana. |
Mar 2028 10 Rev. Ana. 9 EPS Ana. |
Mar 2029 7 Rev. Ana. 6 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
135.78B
est: 134.72B (+0.8%)
|
160.28B
est: 160.16B (+0.1%)
|
244.80B
est: 247.83B (-1.2%)
|
261.84B
est: 263.47B (-0.6%)
|
288.63B
est: 287.20B (+0.5%)
|
292.42B
est: 296.60B (-1.4%)
|
309.28B
est: 312.83B (-1.1%)
|
361.36B
est: 362.99B (-0.5%)
|
447.19B
est: 447.56B (-0.1%)
|
502.67B
est: 500.33B (+0.5%)
|
486.87B
est: 494.77B (-1.6%)
|
506.24B
488.11B – 514.60B
+2.3% YoY
|
460.03B
451.30B – 485.34B
-9.1% YoY
|
447.34B
427.03B – 514.84B
-2.8% YoY
|
461.17B
455.87B – 466.48B
+3.1% YoY
|
470.05B
454.94B – 518.33B
+1.9% YoY
|
| EBITDA |
21.46B
est: 43.92B (-51.1%)
|
36.55B
est: 52.21B (-30.0%)
|
67.54B
est: 80.79B (-16.4%)
|
68.78B
est: 85.89B (-19.9%)
|
75.39B
est: 93.63B (-19.5%)
|
93.39B
est: 96.69B (-3.4%)
|
107.92B
est: 101.98B (+5.8%)
|
132.64B
est: 118.34B (+12.1%)
|
169.75B
est: 145.91B (+16.3%)
|
181.70B
est: 156.81B (+15.9%)
|
90.28B
est: 155.07B (-41.8%)
|
158.66B
152.98B – 161.28B
+2.3% YoY
|
144.18B
141.44B – 152.11B
-9.1% YoY
|
140.20B
133.84B – 161.36B
-2.8% YoY
|
144.54B
142.87B – 146.20B
+3.1% YoY
|
147.32B
142.58B – 162.45B
+1.9% YoY
|
| EBIT |
15.36B
est: 37.71B (-59.3%)
|
30.01B
est: 44.83B (-33.0%)
|
59.72B
est: 69.37B (-13.9%)
|
59.57B
est: 73.74B (-19.2%)
|
64.76B
est: 80.39B (-19.4%)
|
79.18B
est: 83.02B (-4.6%)
|
92.10B
est: 87.56B (+5.2%)
|
114.91B
est: 101.60B (+13.1%)
|
152.30B
est: 125.27B (+21.6%)
|
163.56B
est: 131.54B (+24.3%)
|
63.38B
est: 130.07B (-51.3%)
|
133.09B
128.32B – 135.29B
+2.3% YoY
|
120.94B
118.64B – 127.59B
-9.1% YoY
|
117.60B
112.26B – 135.35B
-2.8% YoY
|
121.24B
119.85B – 122.64B
+3.1% YoY
|
123.57B
119.60B – 136.27B
+1.9% YoY
|
| Net Income |
12.98B
est: 11.34B (+14.4%)
|
24.98B
est: 19.91B (+25.4%)
|
55.79B
est: 50.95B (+9.5%)
|
50.28B
est: 42.22B (+19.1%)
|
51.54B
est: 48.46B (+6.4%)
|
59.70B
est: 54.48B (+9.6%)
|
75.43B
est: 70.78B (+6.6%)
|
80.52B
est: 81.43B (-1.1%)
|
112.72B
est: 113.68B (-0.8%)
|
127.98B
est: 120.95B (+5.8%)
|
50.05B
est: 65.13B (-23.2%)
|
69.77B
65.37B – 78.05B
+7.1% YoY
|
67.75B
60.79B – 72.42B
-2.9% YoY
|
58.87B
51.12B – 63.42B
-13.1% YoY
|
63.66B
53.53B – 69.49B
+8.1% YoY
|
63.23B
60.59B – 71.68B
-0.7% YoY
|
| SGA |
40.82B
est: 28.53B (+43.1%)
|
42.63B
est: 33.92B (+25.7%)
|
60.66B
est: 52.49B (+15.6%)
|
66.35B
est: 55.80B (+18.9%)
|
68.00B
est: 60.83B (+11.8%)
|
65.20B
est: 62.82B (+3.8%)
|
66.62B
est: 66.26B (+0.5%)
|
74.12B
est: 76.88B (-3.6%)
|
86.64B
est: 94.80B (-8.6%)
|
97.39B
est: 108.42B (-10.2%)
|
122.22B
est: 107.21B (+14.0%)
|
109.70B
105.77B – 111.51B
+2.3% YoY
|
99.68B
97.79B – 105.17B
-9.1% YoY
|
96.93B
92.53B – 111.56B
-2.8% YoY
|
99.93B
98.78B – 101.08B
+3.1% YoY
|
101.85B
98.58B – 112.32B
+1.9% YoY
|
| EPS |
24.48
est: 24.14 (+1.4%)
|
47.13
est: 42.39 (+11.2%)
|
105.27
est: 108.45 (-2.9%)
|
97.00
est: 89.88 (+7.9%)
|
100.25
est: 103.15 (-2.8%)
|
118.47
est: 115.96 (+2.2%)
|
151.11
est: 150.67 (+0.3%)
|
162.19
est: 173.34 (-6.4%)
|
230.85
est: 241.98 (-4.6%)
|
266.61
est: 254.46 (+4.8%)
|
106.55
est: 132.50 (-19.6%)
|
151.52
139.09 – 166.07
+14.4% YoY
|
146.84
129.35 – 154.10
-3.1% YoY
|
123.47
108.78 – 134.95
-15.9% YoY
|
134.68
113.91 – 147.85
+9.1% YoY
|
134.55
128.93 – 152.52
-0.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-14 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gyo Sagara | Chief Executive Officer & Chairman of the Board | 142M | male |
| Toichi Takino | President, Chief Operating Officer & Representative Director | 102M | male |
| Toshihiro Tsujinaka | EVice President, Executive Director of Corporate Strategy & Planning, HR Division and Representative Director | 78M | male |
| Masayuki Tanigawa | Corporate Officer & Head of Business Strategy, License | — | — |
| Akira Takada | Corporate Executive Officer & Executive Director of CMC & Production | — | — |
| Shinji Takai | Corporate Officer & Head of Medical Affairs | — | — |
| Takehiro Yamada | Corporate Officer & Head of Risk and Compliance Management Department | — | — |
| Satoshi Takahagi | Senior Director of EHS Promotion & Corporate Officer | — | — |
| Hiromu Habashita | Corporate Officer, Senior Vice President, Discovery & Research | — | — |
| Masaki Ito | Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4528.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
